IMELDA MATA: Open Payments
NPI 1134731268 · CHICO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,541 in 86 payments from 9 companies in 2025. Trend: 2023 $1,121 · 2024 $1,457 · 2025 $1,541
Food & beverage: $1,441Education: $100
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 26 | $504 |
| ABBVIE INC. | 33 | $444 |
| GENZYME CORPORATION | 9 | $199 |
| LEO Pharma Inc. | 7 | $161 |
| Lilly USA, LLC | 4 | $84 |
| Novartis Pharmaceuticals Corporation | 4 | $84 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $25 |
| Incyte Corporation | 1 | $21 |
| UCB, Inc. | 1 | $18 |
Products named: TREMFYA, SKYRIZI, DUPIXENT, ADBRY, TALTZ, COSENTYX, RINVOQ, BOTOX.
Industry payments across CA — which companies pay providers there.
